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Abstract: 
These European Guidelines for Workplace Drug Testing in Urine have been 
prepared and updated by the European Workplace Drug Testing Society 
(EWDTS). The first version of these urine guidelines was published in 2002. 
During these years the guidelines have been followed by many laboratories 
in different European countries and their role has been essential 
particularly in countries lacking legislation for workplace drug testing. In 
2014 EWDTS started a guidelines updating project and published new 
version of the urine guidelines in 2015. Here we represent this new 
updated version of the urine guidelines. The European Guidelines are 
designed to establish best practice procedures whilst allowing individual 
countries to operate within the requirements of national customs and 
legislation. The EWDTS recommends that all European laboratories that 
undertake legally defensible workplace drug testing should use these 
guidelines as a template for accreditation. 
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INTRODUCTION 
The European drug situation has been in constant change during last years.  European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has published current 
information about drug situation in Europe in European Drug Report 2015 [1]. The 
availability of new psychoactive substances has increased on drug market. These drugs 
mimic the effects of established controlled drugs and include substances that are not 
controlled under drug laws. EU countries have been forced to find ways to quickly adapt or 
update their legislation in front of this situation. The majority of these new psychoactive 
substances are synthetic cathinones and synthetic cannabinoids. Also established drugs 
have been increased according to the seizures. The most commonly used drug in Europe 
is cannabis, followed by cocaine, amphetamines and MDMA. [1] [2]. According to EU Drug 
strategy 2013-2020, there is also an increasing trend towards poly-substance use like 
combination of alcohol, prescribed controlled medication and illicit drugs. [3] 
It is estimated that over 80 million adults in the European Union have tried illicit drugs at 
some point in their lives [1]. Drugs are involved in all areas of life, also in workplaces 
where they cause a serious problem for a significant proportion of the working population. 
Drug use ranges from single experimental use to habitual and dependent use. [4] 
European Agency for Safety and Health at Work has published a report of performance 
enhancing drugs, which are used by workers and students under the increasing pressure 
of demands and efficiency at workplaces and during studies [5].  
The main reasons for testing employers according to the employees are to avoid health 
problems and reduced performance of employers, increased sick leaves and work 
accidents, possible damage to equipment and products and risk for company reputation 
[4]. Nowadays also data security of a company is a high priority.  
However, there are still European counties where workplace drug testing is not allowed. 
Also legislation for drug testing is still lacking in many countries. Testing becomes topical 
and rises to headlines especially after bigger accidents. The tragedy of German Wings 
contributed European aviation safety agency (EASA) to publish rapidly an action plan for 
the implementation of the Germanwings Task Force recommendations, which included 
also drug and alcohol testing program [6]. 
There are mainly three different types of testing at workplaces. In pre-employment testing 
an employer is tested for drugs before starting working or signing a contract of 
employment. In random testing any employer may be forced to be tested anytime and it is 
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not informed beforehand. In principle, in pre-employment testing and in random testing the 
employer is not suspected for using drugs. Third kind of situation for drug testing is when 
an employer is suspected of being under the influence of drugs at the workplace. During a 
possible rehabilitation program follow up testing is usual. The practices and legislation 
dealing with all these kind of testing types differ a lot between different countries in 
Europe. In addition, all types of testing are not allowed in all countries. For different types 
of testing also different sample matrixes are appropriate, which are mainly urine, oral fluid, 
hair and blood. Most of the European countries are still lacking legislation for workplace 
drug testing. There has been a strong demand for a common guideline to unify e.g. the 
practices of sample taking, test analyses, quality and interpretation of the results. The first 
guideline of European workplace drug testing society (EWDTS) was published in 2002 for 
urine. In 2014 EWDTS started a guideline updating project, which was completed in 
autumn 2015.  
Main changes in the new version of the guideline comparing to the former version were: 
• New index and structure, which is now similar to the EWDTS guidelines for oral fluid 
[7] and hair [8] 
• In accreditation requirements also the standard EN ISO 15189 in addition to EN 
ISO/IEC 17025 is accepted. However, method validation should be performed 
according to the requirements of EN ISO/IEC 17025. 
• The guideline is relevant to laboratory-based testing only. It is recommended that 
point of collection testing (POCT) devices used should come with national or 
international approvals. 
• Urine collection procedure is described more in detail.  
• Descriptions of key functions and degrees of laboratory personnel is shortened, 
while it is covered by accreditation. Specimen collectors do not have to be health 
care professionals. 
• Requirements for identification of analytes and confirmation of results more in 
detail. 
• New substances were added to the list of recommended substances to be tested 
taking into account current drug situation in Europe. It was not reasonable to give a 
certain minimum list of substances to be tested because of different drug situation 
in different countries. Laboratories should be aware of current drug situation in their 
country and advise the customers to choose an appropriate drug panel. 
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• Cut-off values for established drugs remained mainly the same. However, they are 
recommended maximum cut-off values and laboratories can also use lower ones. 
Cut-off values for new added substances are still under discussion. 
One of the aims of EWDTS is to ensure that workplace drug testing in Europe is performed 
to a defined quality standard and in a legally secured way. The European Guidelines are 
designed to establish best practice procedures whilst allowing individual countries to 
operate within the requirements of national customs and legislation. In addition to these 
guidelines for urine, EWDTS has published also updated versions for oral fluid and hair. 
The EWDTS recommends that all European laboratories that undertake legally defensible 
workplace drug testing should use these guidelines as a template for accreditation. 
 
1 General 
1.1 Introduction 
These guidelines represent an overview of the best practice for European laboratories 
providing urine workplace drug testing services to maintain the legal defensibility of a drug 
test when tested by either an employment tribunal or a court of law. They are designed to 
ensure that the entire drug testing process is conducted to give accurate and reliable 
information about a donor's drug use.  
 
1.2 Objectives 
• To provide a common framework for European providers of urine workplace 
drug testing services. 
• To promote standards by providing guidelines which are accepted at a 
European level.   
• To ensure that the processes undertaken are capable of legal scrutiny. 
• To provide safeguards to protect the dignity of the specimen donors and the 
validity of the specimen. 
• To define common quality assurance and quality control criteria for laboratories 
that are capable of being accredited by an external body. 
• To ensure that the entire drug testing process is conducted to give accurate and 
reliable information about drug use of the donor. 
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1.3 Scope 
These guidelines consider the three key stages of the workplace drug testing process. 
• Specimen collection: Obtaining the urine specimen from the donor  
• Laboratory analysis: Analysis of the sample for the presence of drugs  
• Interpretation: Review and interpretation of the analytical results  
 
1.4 Service Provision 
Where a service provider is contracted to deliver all the stages, they must ensure that the 
minimum criteria in this document are met in all the key areas.  In those instances where a 
customer may undertake some stages of the process within their own organisation (e.g. 
specimen collection or interpretation), the service provider has a 'duty of care' to ensure 
that the customer understands the full implications of the drug testing process.  
The service provider does not have the authority to make decisions regarding the fitness 
for work of any individual being tested. It is recommended that any issues related to fitness 
for work be referred to the company's medical representative.  
 
1.5 Drug testing in Context 
It should be explained to any purchaser of a laboratory drug testing service that drug 
testing should form part of an overall drug policy, which the purchaser has agreed with his 
employees and should have in place before testing is initiated.  
The service provider should have an effective company drugs policy in place.  The policy 
may include drug testing of the staff involved in the analysis and reporting of workplace 
drug testing results. 
 
1.6 Outline of drug testing process 
Specimen collection 
Urine specimens for legally defensible drug testing need to be collected under 
circumstances which respect the dignity of the individual whilst ensuring that the specimen 
is freshly voided.   
Suitable records must be made when the specimen is collected to document that the 
specimen collected and the specimen received by the laboratory is one and the same.  
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This is the first link in the chain of custody process which, when reconstructed at a later 
date, can be used to document that the final result belongs to the specimen collected.  
 
Analysis 
When the specimen is received at the laboratory, checks on the integrity (e.g. colour, 
odour, etc.) of the sample are carried out.  Providing the specimen passes the integrity 
checks a portion of the specimen is taken and screened for the presence of drugs and 
sample validity. If the screen results are all negative no further analysis is necessary.   
However if the screen tests carried out indicate the possible presence of a drug (above a 
predefined cut-off level) a confirmation test to prove or disprove the presence of the drug 
or drug metabolite indicated by the screening test must be carried out on another portion 
of the specimen. 
When a negative result is obtained, either after the screen or confirmation test, it can be 
reported to the customer.  Positive results may require interpretation. 
 
Interpretation 
A laboratory positive result may be due to other reasons than intake of illicit drugs (i.e. 
prescribed or over-the-counter medication or dietary causes).  It requires interpretation that 
is best carried out by the laboratory toxicologist in conjunction with a qualified medical 
practitioner who can consult both with the donor and the donor’s medical practitioner.   
 
Record keeping 
Suitable records must be made during the analytical process to document that the 
specimen received by the laboratory and the specimen, about which the final report is 
written, are one and the same.  All samples which prove positive for the presence of drugs 
and all records of the analytical process, must be kept for an agreed period of time or 
according to the national legislation to allow for any challenges to be made regarding the 
findings.   
If the customer requires an independent toxicological review, the laboratory must make 
available, if requested, the analytical data upon which it based its final report. 
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2 Urine Collection 
2.1 Introduction 
This is the first link in the chain of custody process which, when reconstructed at a later 
date, can be used to document that the final result belongs to the specimen collected. 
The collection process must be carried out by someone formally assessed as competent 
and authorised to carry out the collection. Standard Operating Procedures (SOPs) must be 
written for the collection process, the storage of collection devices, the training of 
Collecting Officers and the shipping of the collected specimen to the laboratory. These 
procedures must be followed precisely. 
 
Collection procedures must cover the following aspects: 
• Privacy and security of the specimen collection site 
• Steps to ensure that the specimen collection is supervised. 
• Steps to protect against tampering and adulteration 
• Identification of the donor giving the specimen 
• Evidence of the written informed consent of the individual to the analysis of the 
specimen (an example is given in Appendix B). 
• Disclosure of recent medication, or evidence that the individual was advised of 
the significance of recent medication. 
• All information is considered as confidential. 
 
All specimens for legally defensible drug testing must be collected under circumstances 
that respect the dignity of the individual whilst ensuring that the sample is freshly voided 
and has not been tampered with in any way. The collection site must be secure and the 
absence of potential interfering substances must be guaranteed. The validity of the sample 
has to be guaranteed. 
Suitable records must be made when the specimen is collected to document that the 
specimen collected and the specimen received by the laboratory is one and the same. 
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Where the customer takes responsibility for the collection process, the service provider 
has a duty of care to ensure that these guidelines are understood. 
 
2.2 Personnel 
Specimens must be collected by suitably trained personnel (Collecting Officers). Although 
no health care professional education is required, a documented training, which includes a 
demonstration of competence, must be undertaken before collections are performed. 
The training must include, at a minimum, instructions on the following: 
• The collection process 
• The storage and transport conditions of samples 
• The chain-of custody process 
• Troubleshooting (i.e. e.g. how to deal with issues like refusal of the test, insufficient 
specimen, suspicion of tampering of the specimen) 
• The responsibility of the collecting officer for maintaining donor privacy, 
confidentiality of information, and specimen integrity. 
• Ethical issues, especially regarding the declaration by the donor of the present use 
of prescribed and over-the-counter medications. 
On successful completion of collector training a person may begin performing collections. 
 
2.3 Urine Collection Kits 
The specimen collection kit should comprise the following components: 
• Chain of custody form. 
• A unique identifier that links the chain of custody form and specimen bottles. 
• Collection cup, demonstrably clean and unused. 
• Temperature measurement device. 
• At least two specimen bottles (A and B), demonstrably clean and unused. 
• Tamper-evident seal for each bottle. 
• Packaging components that satisfy current postal and courier regulations. 
 
2.4 Chain of Custody Form 
The minimum information required on the Chain of Custody Form is: 
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• Unique identification to link the form to the specimen bottles (typically a barcode 
label or code number assigned to the specimen). 
• Information uniquely identifying the donor. 
• Evidence that the donor identity has been confirmed. 
• Evidence that the donor has given informed consent for the specimen to be tested. 
• Date, time and place of collection. 
• Names and signatures of all individuals who had custody of the specimen during 
the collection process. 
• Any medication prescribed or non-prescribed that may have been taken in 
maximum two weeks prior to the specimen being collected. 
• Copies for donor, employer MRO and laboratory.  
 
2.5 Urine Collection Procedures 
The guidelines give the current best practice for the collection of urine specimens for 
analysis. A detailed example of urine collection protocol is in appendix A. 
The procedures must cover the following aspects:  
 
• Identification of the individual giving the specimen.  
• Sufficient information given to the donor about the meaning and content of the drug 
test to enable informed consent to be given to providing a sample for analysis. 
• Privacy and security of the specimen collection site. 
• Steps to ensure that the specimen is freshly voided. 
• Steps to protect against tampering and adulteration. 
• Splitting the specimen into two specimen bottles (A and B). 
• Situations to discard a sample and collect a new one (see Appendix A). 
• Evidence of the written informed consent of the individual to the analysis of the 
specimen (see Appendix B). 
• Disclosure of recent medication, or evidence that the individual was advised of the 
significance of recent medication. 
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3 Laboratory Organisation  
A Quality Management System of the organization / laboratory is required via accreditation 
according to EN ISO/IEC 17025 and/or EN ISO 15189 in fields of forensic toxicology 
and/or workplace drug testing analysis. 
All personnel must have contracts with the institution (Laboratory Organisation) which they 
work for and every person must have agreed to the “confidentiality policy” of the institution 
(in written form). 
 
3.1 Personnel 
All personnel should adhere to the requirements of EN ISO/IEC 17025 and/or EN ISO 
15189 International Standards and as such, only staff who are suitably qualified and 
whose competence has been formally assessed can work within the laboratory. The 
laboratory must maintain accurate job descriptions for managerial, technical and key 
support personnel involved in the analytical tests. 
The laboratory must keep records that establish the individual’s qualifications / 
competency for all functions performed. The individual’s file must include an up-to-date 
curriculum vitae listing educational qualifications and previous employment experience, 
training and competency assessment records for the current tasks performed. Personnel 
performing specific tasks shall be qualified on the basis of appropriate education, training, 
experience and/or demonstrated skills, as required. 
All laboratory personnel must have received training in Health and Safety issues, the 
Control of Substances Hazardous to Health (COSHH) Regulations and other relevant 
legislation. 
The key functions outlined below are identified as the minimum requirement for a 
laboratory to maintain EN ISO/IEC 17025 and/or EN ISO 15189 accreditation for the 
provision of workplace drug testing services and/or forensic toxicology. It is acceptable for 
individuals to have responsibility to carry out more than one role. By virtue of the 
laboratory’s accreditation, it can be accepted that the appropriate qualifications for each 
role are in place.  
NOTE: Role titles may vary between organisations, but the responsibilities will remain the 
same. 
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3.2 Laboratory Security 
Drug testing laboratories must have a robust security system to ensure that no 
unauthorised personnel gain access to the laboratory processes or to areas where 
samples or records are stored as mentioned in EN ISO/IEC 17025 and/or EN ISO 15189. 
Unescorted access to these secured areas must be limited to authorised individuals. The 
laboratory must maintain a record that documents the entry and exit of all visitors to the 
secured laboratory areas. 
The laboratory must maintain a rec rd of all staff who are authorised to enter the secure 
laboratory areas. This list must be reviewed and updated on a regular basis.  
Specimen bottles must be retained within the secure laboratory area until the disposal 
date. 
 
3.3 Laboratory Head 
There must be one person who has overall responsibility for the professional, 
organisational, educational, and administrative activities of the drug testing facility. 
This person is responsible for the day-to-day management of the drug testing laboratory. 
Some of the functions may be delegated to other appropriately qualified personnel but the 
overall responsibility for any delegated functions will remain with the designated 
Laboratory Head (typically the Laboratory Supervisor). 
 
3.4 Authorising Scientist 
A person responsible for the review and certification of pertinent data and quality control 
results, prior to release of accurate and reliable analytical results. 
 
3.5 Laboratory Analyst 
A person responsible for undertaking the day-to-day analytical procedures. 
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3.6 Toxicologist 
A person responsible for interpreting a toxicological analytical result for the customer or 
the customer’s designated Medical Review Officer. 
 
3.7 Expert Witness 
A person to present evidence to administrative or disciplinary proceedings that are based 
on analytical results reported by the laboratory. 
 
3.8 Quality Manager 
A person responsible for quality assurance within the laboratory organisation. 
 
3.9 Other Personnel 
Other technical or non-technical staff who must have the necessary training and skills for 
the tasks assigned. 
 
4 Laboratory Analysis Procedures 
4.1  Process 
When specimens are received at the laboratory, initial checks on the specimen’s chain of 
custody and appearance are carried out. If the specimen passes these checks a portion of 
the specimen in bottle “A” is taken and goes through initial screening tests for the 
presence of drugs. Further testing of sample validity may also take place at this point. 
If the screening results are all negative (below a pre-defined cut-off level) no further 
analyses are necessary.  
However, if the screening tests carried out indicate the possible presence of a drug (above 
a pre-defined cut-off level) a confirmation test to prove or disprove the presence of the 
drug or drug metabolite indicated by the screening test must be carried out on another 
portion of the specimen. 
The screen-only presumptive positive test is not considered to be legally defensible, but 
may report preliminary presumptive positive results as local legislation allows. In the report 
it has to be mentioned that preliminary presumptive positive result may be false positive 
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and requires confirmation.  
If the first analysis is performed by a confirmation-level analysis (mass spectrometry), the 
positive findings have to be retested with another portion of the specimen. 
 
4.2 Chain of Custody 
Laboratories must use chain of custody procedures to maintain control and accountability 
of specimens and aliquots from receipt through completion of testing, reporting of results, 
during storage, and continuing until final disposal of specimens and aliquots.  
Chain of custody records must be maintained on paper or in computerised form.   
 
4.3 Specimen receipt 
The laboratory should receive at least two sealed specimen bottles and a corresponding 
chain of custody form. 
At least one of these (referred to, in this document, as the “B” bottle) must be retained 
unopened and stored in conditions that reflect the storage of the specimen under test 
(referred to, in this document, as the “A” bottle). 
 
When a sample is received in the laboratory: 
• Incoming orders and specimens must be registered by the laboratory.  
• Incoming specimens are immediately checked regarding completeness, 
intactness and suitability for testing. 
• Its packaging must be examined for evidence of tampering in transit. 
• The information on the specimen bottles within the package must be compared 
with the information on the accompanying chain of custody form. 
• Any discrepancies must be noted and, where appropriate, reported immediately 
to the customer. Some minor discrepancies may be tolerated in the 
documentation without termination of the analysis. These must be agreed with 
the customer prior to analysis and should be documented. 
• Appendix C lists examples of fatal flaws in the chain of custody and is provided 
for guidance. Flaws of this nature would normally result in the specimen not 
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being tested. 
 
4.4 Sample processing 
Separate representative portions (aliquots) of the specimen in bottle ‘A’ will be used for the 
screening and confirmation tests. The sample preparation should follow the standard 
operating procedure and the manufacturer’s instructions for the collection system being 
used. Aliquots must be taken in such a manner that excludes the possibility of 
contamination. 
 
Short term storage: samples that are not currently undergoing analysis must be 
refrigerated at 2-8°C. Stability has to be investigated and appropriate measures 
undertaken to ensure the sample is valid for the analysis. 
The A and the B specimens must be stored under identical conditions. 
The quality control requirements in section 67 must be satisfied when conducting either 
screening or confirmation tests, either on single samples or samples grouped in batches. 
 
4.5 Urine Validity Testing 
The aim of validity testing is to demonstrate that the sample submitted for analysis is urine. 
The validity of the sample must be checked either before or during the screening process. 
Creatinine should always be analysed. The laboratory may also test for pH, nitrite, other 
adulterants or use tests to check the adequate functioning of the antibody in the 
immunoassay. 
Determination of the creatinine concentration 
• If the creatinine concentration is less than or equal to 2.0 mmol/L (226 mg/l), the 
specific gravity must be determined.   Acceptable values for specific gravity are 
1.001 – 1.020. 
• Samples with creatinine results within the range 0.5-2.0 mmol/L (56 -226 mg/l) and 
specific gravity results within range, should be reported as dilute.  Because dilution 
of urine may cause false negative results, a comment should be added to negative 
drug testing results. Specimens which screen positive will be confirmed normally 
and reported if confirmed positive (at or over the pre-defined cut-off value). 
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• Specimens with creatinine results less than or equal to 0.5 mmol/L (56 mg/L) and/or 
specific gravity results out of range may be unsuitable for testing and should be 
reported as e.g. “specimen validity failed”. Samples which screen positive will be 
confirmed normally and reported if confirmed positive (at or over the pre-defined 
cut-off value). Negative drug testing results should not be reported. 
 
 
 
 
 
 
Measurement of pH 
• Results within the range 4-9 are deemed to be within a normal range. Results less 
than 4 or greater than 9 should be considered to be adulterated.  Samples falling 
outside this range should be reported as e.g. “Specimen validity failed”.  
• Specimens with pH values outside the normal range which screen positive will be 
confirmed normally and reported if confirmed positive (at or over the pre-defined 
cut-off value). Negative drug testing results should not be reported. 
 
Nitrite test: if the nitrite concentration is determined 
• A nitrite level equal to or above 500 µg/mL is conclusive proof of an adulterated 
sample. The result should be reported as e.g.  “Specimen validity failed”. 
• Specimens with nitrite concentrations above this level which screen positive will be 
confirmed normally and reported if confirmed positive (at or over the pre-defined 
cut-off value). Negative drug testing results should not be reported. 
 
Testing for other adulterants 
• If other tests indicate that the sample has been adulterated, or is otherwise 
unsuitable for analysis then it should be reported as e.g.  “Specimen validity failed” 
• This remark is also reported when the specimen does not fall under the criteria of 
pH, creatinine or nitrite above, yet is still not suitable for testing. This can be due to 
an unidentified interferent or poor specimen quality such as turbidity. 
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5 Analytical Methods and Validation 
5.1 Acceptable Screening Techniques 
Following methods are accepted e.g.: These methods only may be used: 
• Immunoassays 
• Gas Chromatography 
• High Performance Liquid Chromatography 
• All chromatographic techniques coupled to mass spectrometry. 
• Capillary Zone Electrophoresis 
 
5.2 Laboratory Screening Tests 
The initial screening test must shall be based on one acceptable use an appropriate 
technique (see 5.1). The assay test using the selected technique must be validated prior to 
its use. 
Recommended maximum screening cut-off concentrations for workplace drug testing are 
listed in Table 2. These recommended cut-off concentrations may be subject to change 
reflecting advances in technology and knowledge. 
Cut-off concentrations for substances not indicated in Table 2 will need to be agreed with 
the customer taking into account the performance of the assays to be used and the 
pharmacokinetics of the drugs involved. 
All screening test results must be reviewed with regard to the results of the validity tests 
performed. 
Specimens that test negative on all the initial screening tests and pass the validity tests 
must be reported as negative and the specimens can be disposed of as agreed with the 
customer.  Specimens that test negative on all the initial screening tests but fail the validity 
tests may be further investigated to determine the reason why. 
The presumptive presence for any drug following the initial preliminary screen must have 
the presence of the drug or drug metabolite confirmed (refer to section 6.4 Confirmation 
Tests). If the first analysis is performed by a confirmation-level analysis (mass-
spectrometry), the positive findings have to be confirmed and quantified by reanalysis with 
another portion of the specimen. 
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5.3 Standardisation of Laboratory Screening Assays 
All assays must be calibrated against appropriate standards by following laboratory 
protocols based on the manufacturer’s recommendations or validated alternatives. 
The assay must be calibrated against one named compound, and the cross-reactivity to 
other related compounds must be determined. 
The customer must be informed of the limitations of the tests.  
 
5.4 Confirmation Tests 
The presence of the drugs indicated by a positive screening result must be confirmed 
using a chromatographic technique in combination with mass spectrometry (e.g. GC-MS or 
LC-MS). If the first analysis is performed by a confirmation-level analysis (mass 
spectrometry), the positive findings have to be confirmed and quantified by reanalysis with 
another portion of the sample. 
All confirmations must be quantitative. The customer must be informed of the compounds 
detected in the confirmation tests. 
Recommended maximum confirmation cut-off concentrations for workplace drug testing 
are given in Table 3.  
Confirmation cut-off concentrations may be subject to change as advances in technology 
or other considerations warrant identification of substances at other concentrations. When 
a sample is tested for substances not indicated in Table 3, the 
cConfirmation cut-off levels for substances not indicated in Table 3 must be agreed with 
the customer taking into account the performance of the assays to be used (i.e. limit of 
detection and limit of quantification)  and the pharmacokinetics of the drugs involved (i.e. 
different metabolites and their detection times).. 
Specimens that are below the agreed cut-off concentration must be reported negative. No 
further testing for drugs will be undertaken and the specimens must be discarded. 
Specimens that contain drugs and/or metabolites at concentrations greater than or equal 
to the agreed cut-off level must be reported as positive. 
Laboratories must adhere to national and international guidelines that specify additional 
criteria for chromatographic and mass spectral acceptability. 
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5.5 Validation 
All methods must be validated and their suitability for intended purpose must be evaluated 
in accordance with EN ISO/IEC 17025. Laboratories accredited according to EN ISO 
15189 should produce evidence of adequate method validation and certificate of 
participation to Proficiency Test and External Quality Assessment. 
The following parameters have to be determined at least for quantitative confirmation 
analyses and whenever possible, for screening analyses: precision, cut-off verification, 
selectivity, limit of detection, limit of quantification, sensitivity, specificity, stability, 
measurement uncertainty and matrix effects. 
 
5.6 Authorisation and Reporting of Results 
Before any laboratory test result is released, the results and chain of custody 
documentation must be reviewed and certified as accurate and complete by a competent 
member of staff (analytical validation). At a minimum, the report must include the 
specimen identification number and the test result (positive/negative) for each specimen 
submitted. 
Reporting must be managed in accordance with EN ISO/IEC 17025 and/or EN ISO 15189 
requirements. In addition the cut-off used for the test should be included. 
Only drugs that have been confirmed by a recognised confirmation test may be reported 
as positive.  
Specimens that fail integrity or validity tests must be identified to the customer on the 
report. The laboratory must define and agree the meaning of all terms used in the report to 
the customer. Results must be transmitted to the customer’s designated representative in 
a manner that will ensure confidentiality of the information. Laboratory results should not 
be provided verbally. Written or electronic results must be transmitted to the customer’s 
designated representative in a manner that will ensure confidentiality of the information. 
 
5.7  Long-Term Storage of Specimens 
The laboratory must demonstrate that the long term storage conditions of specimens are 
adequate to ensure that analytes are stable over the time period required for any re-test  
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Currently long-term frozen storage ( 20°C or below) indicates that most positive specimens 
will remain suitable for any necessary retest. 
Unless otherwise authorised in writing by the customer, drug testing laboratories must 
retain all specimens confirmed positive in properly secured long-term frozen storage for a 
minimum of 1 year. 
Within this one-year period the customer may request the laboratory to retain the 
specimen for an additional period of time. If no such request is received, the laboratory 
may discard the specimen after the end of 1 year. The laboratory shall be required to 
maintain any specimens known to be under legal challenge for a further agreed period. 
Specimens must be retained within the secure laboratory area until the disposal date 
agreed with the customer. Negative specimens (A+B) may be discarded as per the 
laboratory and customer agreed timetable. 
 
5.8 Records 
The laboratory must maintain and make available for an agreed period, documentation of 
all aspects of the testing process and chain of custody documentation involved in the 
generation of a positive result. 
The required documentation must include: 
• Training and competency records for all individuals authorised to have access 
to specimens and specimen data. 
• Chain of custody forms 
• Quality assessment/quality control records 
• Standard operating procedures  
• All test data (including method validation, calibration curves and calculations for 
determining test results) 
• Maintenance and instrument calibration records 
• Reports 
• Records of proficiency testing and computer generated data 
 
The laboratory will be required to maintain documents for any specimen under legal 
challenge for a further agreed period. 
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Document control must be managed in accordance with EN ISO/IEC 17025 and/or EN ISO 
15189 requirements and records containing details of individuals should be dealt with in 
line with European Data Protection Legislation. 
 
6 Quality Assurance and Quality Control 
6.1 Quality Assurance 
Drug testing laboratories must have a quality management system which encompasses all 
aspects of the testing process including but not limited to: 
• Specimen receipt 
• Chain of custody 
• Security and reporting of results
• Screening and confirmation testing 
• Certification of calibrators and controls 
• Validation of analytical procedures 
 
Quality assurance procedures shall be designed, implemented and reviewed to monitor 
the conduct of each step of the testing process. 
The testing laboratory and all screening and confirmation tests used in Workplace Drug 
Testing must be fully validated and accredited by a recognised external accreditation body. 
When an unaccredited method is used the customer should be informed accordingly. 
 
6.2 Quality Control 
Calibrators and controls shall be prepared using either certified drug reference materials or 
certified standard solutions obtained from where possible two commercial manufacturers 
and should be appropriate to the matrix. If two manufacturers are not feasible then the 
controls should be taken from separate lots from the same manufacturer. 
The laboratory must retain records to demonstrate that all calibrators and controls are 
traceable back to primary standards (if available).  
The calibrators and controls shall be properly labelled as to content, concentration, date 
placed in service and expiry date. 
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All standards (e.g. i.e. pure reference materials, stock standard solutions, purchased 
standards) shall be labelled with the following: 
• Date received (if applicable). 
• Date prepared or opened or placed in service. 
• Expiration date. 
• Lot number of drug reference materials.  
• Initials of the technicians who has prepared the (in house) calibrator etc. 
 
All data acquired on control samples as well lot number of drug reference materials must 
be recorded in such a way as to facilitate interpretation of control results and trends. 
 
6.3  Laboratory Screening Tests 
These are the minimum requirements for the suitable control of all laboratory screening 
tests. 
A system suitability check must be carried out prior to the analysis of samples.  
Assays must be calibrated weekly or when quality control samples indicate poor 
performance. 
Control samples at concentrations of approximately 25% below and above the cut-off 
concentration for each drug group must be included in every batch of samples. These 
must be sourced independently from calibrators. 
Quality control samples must comprise at least 5% of the total number of samples in each 
batch being analysed.  
6.4 Confirmation tests 
These are the minimum requirements for identification of analytes and confirmation of 
results [91] 
6.4.1 Identification 
Mass spectrometry coupled to chromatography 
a) Mass spectrometry coupled to a chromatographic separation method is a very powerful  
combination for identification of an analyte in the sample extract. It simultaneously 
provides retention time, ion/charge ratios and relative abundance (intensity) data. 
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Requirements for chromatography 
b) The minimum acceptable retention time for the analyte(s) under examination should be 
at least twice the retention time corresponding to the void volume of the column. The 
retention time of the analyte in the extract should correspond to that of the calibration 
standard (may need to be matrix-matched) with a tolerance of ± 1 %, for both gas 
chromatography and liquid chromatography (Figure 1). 
Requirements for mass spectrometry (MS) 
c) Reference spectra for the analyte should be generated using the same instruments and 
techniques used for analysis of the samples. If major differences are evident between a 
published spectrum and the spectrum generated within the laboratory, the latter must be 
shown to be valid.  
d) Identification relies on proper selection of diagnostic (characteristic) ions. The (quasi) 
molecular ion is a diagnostic ion that should be included in the measurement and 
identification procedure whenever possible. In general, and especially in single-stage MS, 
high m/z ions are more specific than low m/z ions (e.g. i.e. m/z< 100).  
e) Extracted ion chromatograms of sample extracts should have peaks (exceeding S/N 3:1 
of similar retention time, peak shape and response ratio to those obtained from a 
calibration standard analysed at comparable concentration in the same batch. Shift in 
retention time should not exceed 1% compared to calibration standard. 
Chromatographic peaks from different selective ions for the same analyte must overlap 
with each other. Where an ion chromatogram shows evidence of significant 
chromatographic interference, it must not be relied upon to quantify or identify residues. 
The ion that shows the best signal-to-noise ratio and no evidence of significant 
chromatographic interference should be used for quantification. 
f) In case of full scan measurement, careful subtraction of background spectra, either 
manual or automatic, by deconvolution or other algorithms, may be required to ensure that 
the resultant spectrum of the chromatographic peak is representative. Whenever 
background correction is used, this must be applied uniformly throughout the batch and 
should be clearly indicated. 
g) Different types and modes of mass spectrometric detectors provide different degrees of 
selectivity and specificity, which relates to the confidence in identification. General 
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requirements for identification by MS-methods have been published [91] and should be 
regarded as guidance criteria for identification, not as absolute criteria to prove presence 
or absence of a compound.  
 
h) The relative intensities or ratios of selective ions (full-scan MS or SIM) or product ions 
(MS/MS), expressed as a ratio relative to the most intense (product) ion, should 
correspond to those of the calibration standard at comparable concentrations and 
measured under the same conditions. Matrix-matched calibration solutions may need to be 
used. Table 4 indicates the maximum tolerances for ion ratios. 
i) The variability of ion ratios should preferably be determined from calibration standards 
during initial method validation and subsequently during routine analysis. Diagnostic ions 
should have an ion ratio of > 0.05 (least/most intense ion). 
j) At higher deviation of the relative abundance of a qualifier ion, analysis needs to be 
repeated. If tolerances still remain beyond acceptance criteria, further investigation of 
influences of matrix effects or disturbing compound are recommended –such as standard 
addition experiments or chance of chromatographic system - to verify or to exclude the 
presence of a compound. In these cases complementary interpretation by an experienced 
analyst is recommended. 
k) For a higher degree of confidence in identification, further evidence may be achieved 
from additional mass spectrometric information. For example, evaluation of full scan 
spectra, isotope pattern, adduct ions, additional accurate mass fragment ions, additional 
product ions (in MS/MS), or accurate mass product ions.  
For High resolution (HRMS) the mass resolution shall typically be greater than 10000 for 
the entire mass range at 10% valley (which equates to resolving power of 20000 FWHM 
(full width at half maximum).  
For accurate mass measurements (AMM) the instrument mass error in routine mass 
measurements must be less than 2 mDa and resolution shall typically be greater than 
5000 FWHM. For combination of LC with HR-QToF-MS/MS or other mass spectrometric 
technique with HR-MS/MS the following settings are recommended for mass spectral 
identification based on a mass spectral library (commercial or home-made): 
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For HR-QToF-MS/MS analysis a mass resolution of > 10000 amu with a mass accuracy of 
< 5 ppm and an isotope ratio comparability of better than 80% should be used in routine 
analysis. If comparison to a library is performed with MS/MS spectra, a fit value of > 70 % 
should be used as a threshold, for identification of compounds.   Additionally, 1% tolerance 
of LC-retention time is required (see above, e).  
 
l) The chromatographic profile of the isomers of an analyte or any relevant metabolites 
may also provide evidence. Additional evidence may be sought using a different 
chromatographic separation system and/or a different MS-ionisation technique. 
6.4.2 Confirmation of results 
 
If the initial confirmatory analysis does not provide unambiguous identification or does not 
meet the requirements for quantitative analysis (e.g., ion ratios not in the suspected range, 
or chromatographic interference),, a confirmatory reanalysis of the A-sample is required.  
This may involve reanalysis of the extract or the sample. In cases where a detection 
threshold for a drug is exceeded, a confirmatory analysis of a portion of the B-sample may 
be required by the authorities.  
For unusual analyte/matrix combinations, a confirmatory reanalysis is also recommended. 
The use of different determination techniques and/or confirmation of qualitative and/or 
quantitative results by an independent expert laboratory will provide further supporting 
evidence.  
 
6.5 External Quality Assessment 
The laboratory must take part in appropriate external quality assessment schemes. When 
the scheme is not available, the laboratory has to conduct appropriate inter-laboratory 
testing to ensure appropriate assay performance. 
 
6.6 Sub-contracting 
Drug testing laboratories should carry out all laboratory work with their own personnel and 
equipment. If it is necessary to sub-contract, inter-laboratory transfer of samples is 
performed with strict adherence to chain of custody procedures. The sub-contracted 
laboratory and its methods used must be accredited by a recognised external accrediting 
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body and compliant with these guidelines. Analyses undertaken by sub-contracted 
laboratories must be identified on the test report to the customer. 
 
7 Interpretation of Results  
A confirmed analytical positive result may be due to medication (prescribed or over-the-
counter) or due to dietary causes. An essential part of the drug testing process is the final 
review of analytical results. 
The interpretation is best carried out by a qualified medical professional (e.g.i.e. Medical 
Review Officer) or a Toxicologist (depending on the country-specific situation) (See 
chapter 43). 
7.1 Toxicology Review 
It is mandatory that a toxicologist is available to advise the customer and/or Medical 
Review Officer regarding queries with test results. 
 
7.2 Medical Review 
The Medical Review Officer (MRO) is a medical physician with responsibility for 
interpreting laboratory results together with a toxicologist. Depending on the country-
specific situation a medical physician usually has greater access to medical records than a 
toxicologist and may therefore be in a better position to provide interpretation of positive 
analytical results. 
 
The MRO must have specialist knowledge of and training in 
• specimen collection procedures, 
• analytical procedures, 
• chain of custody and 
• alternative explanations for positive analytical results. 
 
The MRO can issue a negative report for a positive analytical result if the test result is 
likely to be due to the use of declared medication, or a valid alternative medical 
explanation has been found. 
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The service provider may provide access to an independent medical review service. 
 
8 Challenges to Drug Test Results 
In situations where there is a challenge to the results of a confirmed positive drug test 
result, the following guidelines must be used.  
The B specimen should be released for analysis to a drug testing laboratory accredited by 
a recognised external accrediting body and working to these guidelines. This release 
requires authorisation from both the customer/MRO and the donor.  
The release must be supported by chain of custody procedures that can withstand legal 
scrutiny and include information about the findings of the original test (corresponding A 
specimen) and the cut-offs used for the test. 
The original laboratory must retain the residue of the original A specimen and its 
containers so that they can be compared with the B specimen at a later date if required.  
All laboratories that undertake B specimen testing must be able to demonstrate that they 
can accurately determine the concentration of a drug or metabolite at 50% of the 
recommended confirmation cut-off concentration listed in Table 3 (or the cut-off used for 
the original test, whichever is the lower). 
On receipt in the testing laboratory, the B sample should follow chain of custody 
procedures as outlined. It is recommended that the laboratory should carry out validity 
checks outlined prior to carrying out the confirmation analysis. Only those 
drugs/metabolites identified for confirmation testing should be looked for. 
The final report on the B specimen must say either that the result was reconfirmed or failed 
to reconfirm. Confirmation cut-off levels are not to be used as the determinant. There must 
be no comment on the final report that states whether the sample is positive or negative.  
 
 
 
  
Page 26 of 45
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Page 26 of 44 
 
 
9 Appendix  A   
 
Urine Collection Procedure 
 
(Note: Only formally competence tested and authorised persons may act as collecting 
officers. Medical qualification is NOT required for collecting officers.) 
 
I. Collection Site 
Procedures shall provide for a designated collection site to be secure. During the collection 
process the collection site must be dedicated solely to sample collection and comply with 
all local health and safety requirements. 
The circumstances of the collection site should be arranged so that adulteration of the 
specimen is prevented as well as possible. To deter the dilution of specimens at the 
collection site, toilet water colouring agents should be placed in toilet tanks wherever 
accessible or in the toilet bowl, so the reservoir of water in the toilet bowl always remains 
coloured.  Any other sources of water in the enclosure where urination occurs (e.g. taps, 
shower) will be secured prior to collection. At the collection site access must be controlled 
to soap dispenser, cleaning agent, or any other materials that could be used to adulterate 
the specimen. Also paper towel dispensers, ceiling tiles, or other spaces that could be 
used to hide adulterants, must be secured during the specimen collection. 
 
II. Access to Authorised Personnel Only 
Only authorised personnel shall be permitted in any part of the designated collection site 
when urine specimens are being collected or stored. The donor has the right to be 
accompanied with a silent witness, but that should not interfere or delay the collection 
process, nor is the witness permitted to accompany the donor into the enclosure where the 
urination occurs. 
 
III. Chain of Custody 
During the collection process chain of custody forms will be completed fully by the 
collecting officer and donor.  
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IV. Identification of the donor 
When a donor arrives at the collection site, the collecting officer will request that the donor 
presents photographic identification and a signature for comparison. If the donor does not 
have acceptable photographic identification, the collecting officer will obtain a positive 
identification of the donor by an authorised supervisor or manager within the parent 
organisation. If the donor's identity cannot be established, the collecting officer will not 
proceed with the collection. 
 
V. Informing the donor about the test 
The donor has to be informed about the purpose and the content of the test. 
 
VI. Consent of the donor 
The donor gives his/her consent for urine collection and analysis of drugs by signature. If 
the donor refuses to give a sample, a note to this effect should be recorded on the form 
designated for that purpose. Appendix B gives an example of a Donor’s Statement of 
Informed Consent. 
 
VII. Privacy 
Procedures for collecting urine specimens shall allow individual privacy during urination 
and no observed collection is appropriate in normal cases. Donors have to be treated 
equally regardless of gender, ethnicity, or any physical impairment. The process should 
avoid embarrassment but should also be stringent enough to satisfy challenge of the 
specimen integrity and collection process. 
If there is a strong suspicion of specimen adulteration due to not passed specimen validity 
checks and/or the previous specimen, collected from the donor, was has been adulterated, 
the new specimen can be collected under the direct observation of the collecting officer. 
 
VIII. Integrity of the Specimen 
The collecting officer must adopt procedures to minimise the risk of adulteration of the 
specimen during the collection procedure. The following minimum precautions shall be 
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taken to ensure that unadulterated specimens are obtained and correctly identified: 
a. The collecting officer will ask the donor to show that their pockets are empty and 
remove any unnecessary outer garments such as a coat or jacket that might 
conceal items or substances that could be used to tamper with or adulterate the 
donor's urine specimen.  The collecting officer will ensure that all personal 
belongings such as a purse or briefcase remain with the outer garments.  
b. The donor must wash his/her hands with water only prior to urination with inspection 
of the hands afterwards by the collecting officer. 
c. After washing hands, the donor will remain in the presence of the collecting officer 
and will not have access to any unregulated source of water, soap dispenser, 
cleaning agent, or any other materials that could be used to adulterate the 
specimen. 
d. The donor will choose a clean specimen container. The donor may provide his/her 
specimen in the privacy of a toilet cubicle or otherwise partitioned area that allows 
for individual privacy.  The collecting officer will remain outside the cubicle until the 
specimen is collected.  The donor will be instructed not to flush the toilet until the 
specimen is handed to the collecting officer. 
e. The collecting officer will note any unusual behaviour of the donor on the chain of 
custody form. 
f. Upon receiving the specimen from the donor, the collecting officer will: 
o Check the volume of urine in the specimen container 
- The sufficient volume is approx. 20 millilitres (mL) or more. 
- If the volume is less than 20 mL, the specimen will be discarded and 
a second specimen will be collected.  The donor may be offered a 
reasonable amount of liquid to drink for this purpose (max 2 times 
250 mL in 1 hour, not to exceed a maximum of 0.5 litre).  In these 
circumstances a donor should normally be able to provide a 20 mL 
urine specimen within 2 to 3 hours.  
- The samples must not be combined to provide a sufficient volume. 
- If the donor fails to provide a specimen within this time period the 
collecting officer will contact the appropriate authority to obtain 
guidance on the action to be taken. 
o Check the temperature of the urine specimen.   
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- The temperature-measuring device used must accurately reflect the 
temperature of the specimen and not contaminate the specimen.  
The time from urination to temperature measurement is critical and in 
no case should exceed 4 minutes. 
- The acceptable range of the temperature is 32°C -38°C. 
- A temperature outside the acceptable range is a reason to be 
suspicious that the donor may have altered or substituted the 
specimen. Another specimen will be obtained as soon as possible 
and both specimens will be forwarded to the laboratory for testing.  
- If there is a strong suspicion of adulteration and/or the previous 
sample was adulterated the specimen can be collected under the 
direct observation of a collecting officer.  
o Inspect the specimen to determine its colour and appearance for any signs of 
contaminants.   
- Any unusual findings will be noted on the chain of custody form. 
- If there is any reason to believe that a donor may have adulterated, 
altered or substituted the specimen, another specimen will be 
obtained as soon as possible and both specimens will be forwarded 
to the laboratory for testing.  
- If there is a strong suspicion of adulteration and/or the previous 
sample was adulterated the sample can be collected under the direct 
observation of a collecting officer. 
g) Both the donor and the collecting officer will keep the specimen container / 
specimen bottles in view at all times prior to the urine specimen being sealed and 
labelled. 
h) The specimen is split into a minimum of two specimen bottles. When the specimen 
is transferred from the specimen container to the specimen bottles, it will be poured 
and the collecting officer will request the donor to observe the transfer of the 
specimen and the attachment of the tamper-evident seal/tape on the bottles.  The 
tamper-evident seal ensures that any tampering with the specimen will be evident to 
laboratory personnel during the laboratory receipt. 
i) Direct contact tests (e.g. pH) can only be carried out on the residue of the specimen 
after the sample has been split and sealed into specimen bottles. 
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o The acceptable range of pH is 4-9.  The appropriate pH measuring device 
covers the whole pH-range (e.g. i.e.1-14) to be able to measure pH outside 
the acceptable range. 
o A pH value outside of the acceptable range is a reason to be suspicious that 
the donor may have altered the specimen. Another specimen will be 
obtained as soon as possible and both specimens will be forwarded to the 
laboratory for testing.  
o If there is a strong suspicion of adulteration and/or the previous specimen 
was adulterated the sample can be collected under the direct observation of 
a collecting  
officer. 
j) A minimum of two sealed specimens together with the corresponding chain of 
custody documentation in a tamper evident container must be dispatched to the 
laboratory.  One bottle will be used for the drug test while the second bottle will 
remain sealed at the analytical laboratory in case the donor wishes to challenge a 
positive result. 
k) At an appropriate time after the urine specimen has been collected and sealed into 
the transport bottles the collecting officer will invite the donor to wash his/her hands. 
l) The specimen bottle will have an identification label that contains at a minimum the 
date, the donor's specimen number and the donor’s signature/initials. The collecting 
officer will enter all information on the chain of custody form to identify the origin of 
the specimen.  Both specimen bottles and all pages of the chain of custody will be 
labelled at the time of collection with a unique identifier. 
m) The collecting officer will ask the donor questions relating to the drugs and 
medicines consumed within a maximum of 14 days prior to the provision of the 
urine specimen.  These questions will be specific and wide ranging covering areas 
such as medications prescribed or dispensed by a doctor, dentist or hospital 
department and over-the-counter preparations. All information is written down to the 
chain of custody form. 
n) The donor will be asked to read and sign a statement on the chain of custody form 
certifying that the specimen identified on the form was in fact the specimen provided 
by the donor and giving informed consent for the work to be undertaken.  Appendix 
B gives an example of a Donor’s Statement of Informed Consent. 
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o) The collecting officer will complete the specimen chain of custody form and 
package with the urine specimen ready for dispatch together to the analytical 
laboratory as soon as possible.  If the specimen is not dispatched at once, the 
collecting officer during storage prior to dispatch must give appropriate 
consideration to the temperature and security of the specimens. It is advised that 
the specimens should be stored at 4°C (do not freeze) whenever possible. 
p) Other pages of the chain of custody form will be given/forwarded to the appropriate 
persons. 
q) The collecting officer and the donor will be present throughout the procedures 
outlined in the paragraphs of this section. 
 
IX. Exceptional situations 
a. The donor is not able to give a sample 
The donor may be offered a reasonable amount of liquid to drink for this purpose 
(max 2 times 250 mL in 1 hour, not to exceed a maximum of 0.5 litre). In these 
circumstances a donor should normally be able to provide a 20 mL urine specimen 
within 2 to 3 hours.  If the donor fails to provide a specimen within this time period 
the collecting officer will contact the appropriate authority to obtain guidance on the 
action to be taken. 
b. The donor wants to give the sample later 
The collecting officer must not allow the donor to leave the collection site and come 
back later to provide a specimen. The collecting officer will contact the appropriate 
authority to obtain guidance on the action to be taken. 
c. Admission of illegal drug use 
If the donor admits illegal drug use, this should be noted on the chain of custody 
form. 
 
X. Transportation to Laboratory 
Collecting officers will arrange to dispatch the collected specimens to the drug-testing 
laboratory. The specimens will be placed in containers designed to minimise the possibility 
of damage during shipment and packed properly to comply with local/international mail 
and courier regulations for biological specimens. Since specimens and the corresponding 
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documents are sealed in packages that would indicate any tampering during transit to the 
laboratory by couriers, carriers, and postal services, usually there is no requirement for 
documented chain of custody procedures for the transport of the package. 
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10 Appendix B  
 
Example of a Donor’s Statement of Informed Consent 
I confirm that I have received information about the meaning and content of the drug test. I 
confirm that I have provided a freshly voided urine specimen to the specimen collector. I 
have observed the specimen being placed and sealed in the specimen bottles and I 
confirm that the information on this form and on the specimen labels is correct. I hereby 
give permission for a minimum of two sealed specimen containers to be sent to the 
laboratory and I consent that they be tested for evidence of drug use and for tests to be 
carried out to confirm the validity of the sample. Furthermore, I understand that the results 
will be communicated confidentially to the employer or a designated representative. 
 
I consent to the above. 
 
Donor’s Name (Block Capitals):  _____________________________ 
Donor’s Signature:   _____________________________ 
Date:    _____________________________ 
Donor’s identifier on the specimen labels  
(if different from above):   _____________________________ 
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11 Appendix C   
Some examples of fatal flaws in the Chain of Custody 
 
1. A unique identifier (e.g. barcode) mismatches or absent 
2. No documentation received with the sample 
3. No written consent to test from the donor 
4. Seals broken or tampered with on any bottle 
5. No seals 
6. Only 1 sample received 
7. Insufficient sample for complete analysis 
8. Leaking sample 
9. No collecting officer name and signature on the chain of custody form
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Table 1 Definitions 
For purposes of these guidelines the following definitions have been adopted:  
Adulteration  
See Tampering 
Aliquot 
A fractional part of a specimen used for testing.  It is taken as a sample 
representing the whole specimen. 
Authorising 
Scientist 
A person who reviews all pertinent data and quality control results in 
order to attest to the validity of the laboratory's test reports. 
Calibrator 
A solution of known concentration used to calibrate a measurement 
procedure or to compare the response obtained with the response of a 
test sample/sample.  The concentration of the analyte of interest in the 
calibrator is known within limits ascertained during its preparation.  
Calibrators may be used to establish a calibration curve over a 
concentration range of interest.  
Chain of 
Custody 
Procedures to account for each specimen by tracking its handling and 
storage from point of collection to final disposal.  These procedures 
require that the donor identity is confirmed and that a chain of custody 
form is used from time of collection to receipt by the laboratory. Within 
the laboratory appropriate chain of custody records must account for 
the specimens until disposal.  
Chain of 
Custody 
Form 
A form used to document the procedures from time of collection until 
receipt by the laboratory.   
Collecting 
officer 
A person trained to collect specimens from donors. 
Collection 
Site 
A place where individuals present themselves for the purpose of 
providing a specimen for analysis.  
Confirmation 
Test 
An analytical procedure to identify and quantify the presence of a 
specific drug or metabolite which is independent of the initial test and 
which uses a different aliquot, technique and chemical principle from 
that of the screen test in order to ensure reliability and accuracy. 
Customer The organisation requesting the drug testing service. 
Cut-off  
A concentration level set to determine whether the sample is positive or 
negative for the presence of a drug. 
Donor The individual from whom a urine specimen is collected.  
Laboratory The facility providing the analytical services to detect drugs of abuse. 
Negative 
result 
A result reported by the laboratory that indicates that either no drug or 
drug metabolite is present in the specimen or that any drug or drug 
metabolite present is below the cut-off. 
Observed 
Collection 
A donor gives the specimen under the direct observation of the 
collecting officer. 
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Positive 
result 
A result reported by the laboratory as positive means that there is 
conclusive evidence that a drug or drug metabolite is present in the 
specimen tested at a level greater than or equal to the confirmation cut-
off concentration. 
Quality 
control 
sample 
A sample used to evaluate whether or not an analytical procedure is 
operating within pre-defined tolerance limits.  
Medical 
Review 
Officer (MRO) 
A medical physician responsible for receiving laboratory results from 
the drug-testing laboratory who has knowledge of substance abuse 
and has appropriate training or experience to interpret and evaluate an 
individual's positive test result, in light of declared information.  
Sample 
A representative portion of a specimen submitted used by a laboratory 
for testing. 
Screening 
Test 
A test to eliminate negative specimens from further consideration and 
to identify the presumptive positive specimens that require confirmation 
testing. 
Service 
Provider 
The organisation contracted to provide the drug testing service.  This  
may be a laboratory, or a third party providing other elements of the  
service, and sub-contracting the tests to another laboratory. 
 
Specimen The portion of urine that is collected from a donor. 
Standard (1) 
A reference material of known purity or a solution containing a 
reference material at a known concentration. 
Standard (2) 
An agreed protocol or procedure (EN ISO/IEC 17025 and EN ISO 
15189) 
Standard 
Operating 
Procedure 
(SOP) 
A written document giving the detailed steps to be followed when 
undertaking a particular task (e.g. the analysis of a given drug or drug 
metabolite in a urine specimen). 
Tampering 
Any process by which an individual knowingly interferes with (or 
attempts to interfere with) the processes of specimen collection, 
transport or analysis with the intention of avoiding a legitimate test 
result.  The actions undertaken can include (but are not limited to) the 
addition of water or foreign substances to the specimen, specimen 
substitution, damaging bottle seals or packaging and the deliberate 
consumption of interfering substances or copious volumes of water 
prior to specimen collection. 
Toxicologist 
 
A person responsible for interpreting a toxicological analytical result for 
the customer or the customer’s designated Medical Review Officer. 
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Table 2 Recommended Substances and Maximum Cut-Off Concentrations for 
Screening Tests in Urine 
 
The purpose of the cut-offs’ of listed substances is due to a longer detection time/window. 
It is a recommendation of the upper limit for cut-off concentrations. In the list below, where 
the value is given, this is the maximum recommended cut-off. 
 
ng/mL 
Amphetamines group  500 
Barbiturates  200  
Benzodiazepines group 200 
Buprenorphine  5  
Cannabis metabolites 50 
Cocaine metabolites 150 
EDDP (or methadone) 
100 
(300) 
LSD or metabolites 1 
Opiates (total)  300 
Phencyclidine  25  
Propoxyphene or metabolites  300  
 
Cut-off under investigation / discussion:   
Gammahydroxybutyrate (GHB) - 
Ketamine - 
Other opioids (e.g. oxycodone, hydromorphone, tramadol, fentanyl, 
tilidine) 
- 
Pregabalin - 
Synthetic cannabinoids - 
Synthetic cathinones (MDPV etc.) - 
Z-Drugs (Zopiclone, Zolpidem, Zaleplon) - 
 
 
Page 40 of 45
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Page 40 of 44 
 
 
Note:  
1. The laboratory has to take into account country-specific differences in the drug-
panel they are using. 
2. These recommended cut-off values may be subject to change as advances in 
technology or other considerations warrant identification of these substances at 
other concentrations. 
3. Cut-off levels for substances not indicated in Table 2 will need to be agreed with the 
customer taking into account the performance of the assays to be used. The 
toxicologist/ laboratory have to explain the meaning to the customer. 
4. When using immunological analyses the differences in cross-reactivity of different 
substances have to be noted. 
5. The laboratory is responsible for remaining aware of local drug trends and has a 
responsibility to use this knowledge to advise the customer of the most appropriate 
substances to be included in the drug testing panel.  
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Table 3 Recommended Substances and Maximum Cut-Off Concentrations for 
Confirmation Tests in Urine 
 
The purpose of the cut-offs’ of listed substances is due to a longer detection time/window. 
It is a recommendation of the upper limit for cut-off concentrations. In the list below, where 
the value is given, this is the maximum recommended cut-off. 
 ng/mL 
Amphetamines   
Amphetamine (d+ l) 200 
Methamphetamine  200 
MDA 200 
MDMA  200 
Other members of the amphetamine group 200 
Benzodiazepines or their metabolites   
Alprazolam 100 
Bromazepam 100 
Clonazepam 100 
Diazepam 100 
Flunitrazepam 100 
Flurazepam 100 
Lorazepam 100 
Lormetazepam 100 
Midazolam 100 
Nitrazepam 100 
Nordiazepam 100 
Oxazepam  100 
Phenazepam 100 
Temazepam  100 
Opiates    
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Morphine  300 
Codeine  300 
6-Monoacetylmorphine  10 
Dihydrocodeine 300 
Cannabis   
Cannabis metabolite (THC-COOH)   15 
Cocaine  
Cocaine metabolite (Benzoylecgonine) 100 
Methadone  
Methadone (d+l)  250 
EDDP 75 
Other drugs:  
Barbiturates  150 
Buprenorphine or metabolite  2 
LSD or metabolites 1 
Phencyclidine  25  
Propoxyphene or metabolites  300 
Cut off under investigation / discussion:  
Gammahydroxybutyrate (GHB) - 
Ketamine - 
Other opioids (at least Oxycodone, Hydromorphone, Tramadol , Fentanyl, 
Tilidine) 
- 
Pregabalin - 
Synthetic cannabinoids - 
Synthetic cathinones (MDPV etc.) - 
Zaleplon - 
Zolpidem - 
Zopiclone - 
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Note: 
1. The laboratory has to take into account country-specific differences in the drug-
panel they are using. 
2. These recommended cut-off values may be subject to changes as advances in 
technology or other considerations warrant identification of these substances at 
other concentrations. 
3. Cut-off levels for substances not indicated in Table 3 will need to be agreed with the 
customer taking into account the performance of the assays to be used. The 
toxicologist/ laboratory has to explain the relevance of the cut-offs to the customer. 
4. The laboratory is responsible for keeping abreast of local drug trends and  advising 
the customer regarding relevant drugs for inclusion in the drug testing panel 
5. The Limit of Quantification (LOQ) for each drug has to be no more than 50 % of the 
confirmation cut-off level. 
6. The laboratory has to be able to determine d- and l-amphetamines, if required. 
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Table 4 Recommended maximum tolerances for ion ratios using different MS 
techniques [102, 113] 
 
Ion ratio  
(least/most intense ion) 
Maximum tolerance 
(relative) for GC-EI-MS 
Maximum tolerance (relative) 
for GC-CI-MS, GC-MS
n
,         
LC-MS, LC-MS
n**
 
>50 % 20 % 20 % 
>20 - 50 % 20 % 25 % 
>10 - 20 % 25 % 30 % 
≤10 % 50 % 50 % 
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Figure 1 
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≤ 0.01 
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